Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation
Open Access
- 27 June 2013
- Vol. 99 (16), 1158-1165
- https://doi.org/10.1136/heartjnl-2013-304185
Abstract
Objectives This study was designed to delineate the role of implantable cardioverter defibrillator (ICD) therapy for the primary and secondary prevention of sudden cardiac death in patients listed for heart transplantation. Setting Retrospective observational multicentre study. Patients 1089 consecutive patients listed for heart transplantation in two tertiary heart transplant centres were enrolled. Of 550 patients (51%) on the transplant list with an ICD, 216 had received their ICD for the primary prevention of sudden cardiac death and 334 for secondary prevention. 539 patients did not receive an ICD. Intervention Treatment with or without an ICD was left to the discretion of the heart failure specialist. Main outcome measure All-cause mortality. Results ICDs appear to be associated with a reduction in all-cause mortality in patients implanted with the device for primary and secondary prevention compared to those without an ICD despite a median time on the waiting list of only 8 months (estimated 1-year: 88±3% vs 77±3% vs 67±3%; p=0.0001). A Cox regressional hazard model (corrected for age, sex, underlying heart disease, atrial fibrillation, cardiac resynchronisation therapy, New York Heart Association (NYHA) class, ejection fraction, co-medication and year of listing) suggested an independent beneficial effect of ICDs that was most pronounced in patients who had received an ICD for primary prevention (HR 0.4, 95% CI 0.19 to 0.85; p=0.016). Conclusions ICD implantation appears to be associated with an immediate and sustained survival benefit for patients awaiting heart transplantation.Keywords
This publication has 22 references indexed in Scilit:
- The Editor's Roundtable: Implantable Cardioverter-Defibrillators in Primary Prevention of Sudden Cardiac Death and Disparity-Related Barriers to ImplementationThe American Journal of Cardiology, 2011
- Non–Evidence-Based ICD Implantations in the United StatesJama-Journal Of The American Medical Association, 2011
- Selection of Cardiac Transplantation Candidates in 2010Circulation, 2010
- Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatmentEP Europace, 2010
- Utilization of Defibrillators and Resynchronization Therapy at the Time of Evaluation at a Heart Failure and Cardiac Transplantation CenterPacing and Clinical Electrophysiology, 2010
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic SurgeonsJournal of the American College of Cardiology, 2008
- ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac DeathJournal of the American College of Cardiology, 2006
- Improved Survival of Cardiac Transplantation Candidates with Implantable Cardioverter Defibrillator Therapy:Journal of Cardiovascular Electrophysiology, 2003
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002